Highlight
- SOX9 transcription factor is highly expressed in spasmolytic polypeptide-expressing metaplasia (SPEM) cells, key players in gastric metaplastic progression.
- Genetic deletion of Sox9 in mouse models blocks chief cell transdifferentiation into SPEM cells, halting metaplasia and carcinogenesis.
- A specific TOP2A-positive SPEM subpopulation implicated in metaplasia progression and stromal recruitment depends on SOX9.
- SOX9-driven SPEM plasticity offers a novel and potential therapeutic target to mitigate gastric cancer risk.
Study Background
Gastric cancer (GC) remains a major global health challenge, ranking among the leading causes of cancer-related mortality worldwide. Its development is typically preceded by a well-characterized cascade of premalignant gastric mucosal changes, among which pyloric metaplasia, particularly spasmolytic polypeptide-expressing metaplasia (SPEM), has been recognized as a critical precursor lesion. SPEM arises through transdifferentiation of gastric chief cells, a process marking cellular plasticity that ultimately contributes to neoplastic transformation within the gastric mucosa. Currently, there are no effective therapeutic strategies that specifically target this early metaplastic process to prevent gastric cancer progression, underscoring an unmet clinical need.
Study Design
The study by Guenther et al. employs sophisticated murine genetic models to dissect the role of SOX9, a transcription factor overexpressed in SPEM cells, in gastric carcinogenesis. Two conditional Sox9 knockout mouse models were created: GIFrtTA/+;TetO-CreTg/+;Sox9flox/flox (GCS) for studying metaplasia post-mucosal injury and GIFrtTA/+;TetO-CreTg/+;LSL-KrasG12DTg/+;Sox9flox/flox (GCKS) for assessing cancer development progression. Sox9 deletion effects were analyzed using immunofluorescence assays and cutting-edge single-cell RNA sequencing (scRNA-seq). Human gastric tissue microarrays provided translational confirmation. Additionally, SPEM organoids helped identify SOX9 downstream regulatory genes governing lineage plasticity.
Key Findings
SOX9 Expression in SPEM Cells
The study confirmed elevated SOX9 expression in SPEM cells within both human and murine metaplastic gastric tissues, establishing its relevance to human disease.
Impact of SOX9 Deletion on Metaplasia Development
Chief cells lacking SOX9 failed to undergo transdifferentiation into SPEM cells in response to both acute and chronic gastric injury. This represents a critical blockade of metaplastic initiation, indicating SOX9 as indispensable in the earliest cellular transformation stage.
SOX9 and Gastric Carcinogenesis
In the Kras-driven GCKS model, SOX9 knockout profoundly impeded metaplastic progression to gastric cancer. Notably, the distinct SPEM subpopulation expressing TOP2A, identified via scRNA-seq, which is linked to metaplasia advancement and fibroblast recruitment, was absent. The normal gastric cell lineages were restored, suggesting SOX9 absence fully abrogated the pathological evolution toward neoplasia.
Identification of SOX9-Regulated Genes
The organoid studies uncovered putative downstream target genes of SOX9 involved in regulating cell lineage plasticity, providing molecular insights into how SOX9 orchestrates the metaplastic phenotype and progression.
Expert Commentary
This work advances our understanding of gastric carcinogenesis by pinpointing SOX9 as a master regulator of cell plasticity during metaplastic transition. The findings underscore the functional necessity of SOX9 for SPEM cell lineage evolution and reinforce the concept that blocking cellular plasticity can intercept early cancer development. However, therapeutic translation demands careful evaluation, given SOX9’s role in normal tissue homeostasis. Future studies should address the potential adverse effects of SOX9 inhibition and optimize targeting specificity.
Conclusion
Guenther et al. provide compelling evidence that SOX9-driven SPEM plasticity is integral to the pathogenesis and progression of gastric metaplasia and subsequent cancer development. Therapeutically targeting SOX9 or its downstream signaling pathways could represent an innovative strategy for preventing gastric cancer by halting the earliest metaplastic changes. This approach opens a promising avenue for precision medicine aimed at intercepting gastric carcinogenesis at a critical yet previously untargeted stage.
Funding and ClinicalTrials.gov
The original study was published in Gastroenterology with no specific funding statements provided in the abstract. The article does not report clinical trials. Further investigation is warranted to explore clinical application potential.
References
Guenther AA, Ruelas A, Caldwell B, Cho Y, Zhang C, Jang B, Duncan BC, Romero-Gallo J, Busada JT, Peek R, Choi E. SOX9-driven SPEM cell lineage plasticity is a potential therapeutic target that mitigates risk of metaplastic progression to gastric cancer. Gastroenterology. 2026 Jul 14; PMID: 42448241.
Additional relevant literature:
– Mills JC, Goldenring JR. Chronic inflammation and gastric cancer: cell plasticity, stem cells, and differentiation as origins of neoplasia. Annu Rev Pathol. 2017;12:27-53.
– Nomura S, Yamaguchi T, Honda S, et al. Single-cell transcriptome analysis reveals plasticity and heterogeneity of gastric mucosal cells in premalignant lesions. Gut. 2021;70(9):1745-1757.
